Abstract | BACKGROUND:: OBJECTIVES AND METHODS:: ATLAS ACS 2-TIMI 51 was a double-blind, placebo-controlled clinical trial that randomized ACS patients to either rivaroxaban 2.5 mg b.i.d., rivaroxaban 5 mg b.i.d., or placebo plus standard-of-care antiplatelet therapy for a mean of 13.1 months and up to 31 months ( N=15,526). This post-hoc analysis evaluates the safety and efficacy of rivaroxaban among biomarker-positive ACS patients with and without a history of prior stroke of transient ischemic attack in the ATLAS ACS 2-TIMI 51 trial. RESULTS:: A total of 12,626 biomarker-positive ACS patients were included in this analysis. Among biomarker-positive patients without a prior history of stroke or transient ischemic attack, rivaroxaban 2.5 b.i.d. was associated with a reduction in the primary efficacy endpoint (composite of cardiovascular death, myocardial infarction, or stroke) as compared with placebo (hazard ratio=0.80, 95% confidence interval (0.68-0.94), p=0.007) at the expense of an increase in non- coronary-artery-bypass-graft-related Thrombolysis in Myocardial Infarction major bleeding (1.9% vs. 0.7%, p<0.0001), but not a significant increase in either intracranial hemorrhage (0.4% vs. 0.2%, p=0.11) or fatal bleeding (0.1% vs. 0.3%, p=0.16). CONCLUSION::
|
Authors | Serge Korjian, Eugene Braunwald, Yazan Daaboul, Freek Verheugt, Christoph Bode, Michal Tendera, Purva Jain, Alexei Plotnikov, Paul Burton, C Michael Gibson |
Journal | European heart journal. Acute cardiovascular care
(Eur Heart J Acute Cardiovasc Care)
Vol. 8
Issue 2
Pg. 186-193
(Mar 2019)
ISSN: 2048-8734 [Electronic] England |
PMID | 29249166
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Biomarkers
- Factor Xa Inhibitors
- Platelet Aggregation Inhibitors
- Troponin
- Rivaroxaban
|
Topics |
- Acute Coronary Syndrome
(complications)
- Administration, Oral
- Biomarkers
(blood)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Factor Xa Inhibitors
(administration & dosage)
- Follow-Up Studies
- Humans
- Platelet Aggregation Inhibitors
(administration & dosage)
- Rivaroxaban
(administration & dosage)
- Secondary Prevention
(methods)
- Thrombolytic Therapy
(methods)
- Thrombosis
(blood, etiology, prevention & control)
- Time Factors
- Treatment Outcome
- Troponin
(blood)
|